(219 days)
TestPack® +Plus Strep A
Not Found
No
The device description details a standard immunoassay based on antibody-antigen binding and visual line formation, with no mention of computational analysis, algorithms, or learning processes. The performance studies focus on analytical sensitivity and specificity, typical for this type of test, and there is no mention of AI/ML-specific metrics or training/test sets.
No
The device is a rapid immunoassay for the qualitative detection of Streptococcal A antigen, intended as an aid in diagnosis, not for treatment or therapy.
Yes
The "Intended Use / Indications for Use" section states that the device is "intended for use...as an aid in the diagnosis of Group A Streptococcal pharyngitis." This directly indicates its diagnostic purpose.
No
The device description clearly describes a physical immunoassay kit that uses gold dye and a membrane to detect antigens, which is a hardware-based diagnostic method.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it's for the "qualitative detection of Streptococcal A antigen from throat swabs, or the confirmation of beta-hemolytic colonies obtained from blood agar plates." This involves testing samples taken from the human body (in vitro).
- Purpose: It's intended "as an aid in the diagnosis of Group A Streptococcal pharyngitis." This is a diagnostic purpose.
- Device Description: The description details an "immunoassay" that detects an "antigen" in a sample. This is a common method used in in vitro diagnostics.
- Sample Type: It uses "throat swabs" and "beta-hemolytic colonies obtained from blood agar plates," which are biological samples.
All of these characteristics align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Trinity Biotech Uni-Gold™ Strep A Test Kit is a rapid immunoassay for the qualitative detection of Streptococcal A antigen from throat swabs, or the confirmation of beta-hemolytic colonies obtained from blood agar plates.
The Trinity Biotech Uni-Gold™ Strep A Test Kit is intended for use in hospital laboratories and physicians' offices as an aid in the diagnosis of Group A Streptococcal pharyngitis.
Product codes
GTZ, GTY
Device Description
Immunoassay: Strep A antigen, when present, binds to the anti-Strep A antibody conjugated to a gold dye. As this complex travels along the membrane, it becomes immobilized at the test region, resulting in the formation of a red line. Excess antibodygold conjugate further migrates along the membrane and binds to the control region, forming another red line. In the absence of Strep A antigen, a red line will only be formed at the control region.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
throat
Indicated Patient Age Range
Not Found
Intended User / Care Setting
hospital laboratories and physicians' offices; professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Laboratory studies were conducted to evaluate analytical sensitivity (lowest limit of detection) and analytical specificity (cross-reactivity testing from potential interferents).
Analytical Sensitivity: Serial dilutions were prepared from colonies of Strep A cultures, and were tested with the Uni-Gold™ Strep A test Kit until the interpretations became "negative." The assay demonstrated a sensitivity of 1.0 x 10^5 cells/swab.
Analytical Specificity: The Uni-Gold™ Strep A Test Kit was used to test the following organisms at concentrations of approximately 1 x 10^6. Negative results were obtained in all cases. NOTE: Staphylococcus aureus was tested at 1 x 10^6 organisms. Organisms tested: Bordetella pertussis, Branhamella catarrhalis, Candida albicans, Corynebacterium diphtheria, Escherichia coli, Hemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Lancefield group B, Streptococcus pyogenes, Lancefield group C, Streptococcus pyogenes, Lancefield group D, Streptococcus pyogenes, Lancefield group F, Streptococcus pyogenes, Lancefield group G, Streptococcus sanguis.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 1.0 x 10^5 cells/swab
Predicate Device(s)
TestPack® +Plus Strep A, (TestPack), Abbott Laboratories Inc.
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3740
Streptococcus spp. serological reagents.(a)
Identification. Streptococcus spp. serological reagents are devices that consist of antigens and antisera (excluding streptococcal exoenzyme reagents made from enzymes secreted by streptococci) used in serological tests to identifyStreptococcus spp. from cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by bacteria belonging to the genusStreptococcus and provides epidemiological information on these diseases. Pathogenic streptococci are associated with infections, such as sore throat, impetigo (an infection characterized by small pustules on the skin), urinary tract infections, rheumatic fever, and kidney disease.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
0
2/11/99
Image /page/0/Picture/1 description: The image shows the text "K982373" in a handwritten style on the left side. On the right side, there is a logo for "Trinity biotech" with the word "Trinity" in a bold, sans-serif font inside a black triangle. Below the triangle, the word "biotech" is written in a smaller, sans-serif font. The bottom of the image contains some illegible text.
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K982373.
Submitter Information (21 CFR 807.92(a)(1)) Trinity Biotech, plc Submitter: IDA Business Park Bray County Wicklow, Ireland
Contact:
Dr. Jim Walsh Chief Operating Officer Trinity Biotech, plc phone: 011 353 1 276 9800 011 353 1 276 9888 fax:
November 19, 1998 Summary Date:
Name of Device and Classification (21 CFR 807.92(a)(2)) Uni-Gold™ Strep A Test Kit Name (trade):
Streptococcus spp. serological reagents Name (usual):
21 CFR 866.3740, Class I, GTZ Classification:
Identification of Legally Marketed Predicate Device(s) (21 CFR 807.92 (a)(3))
The Uni-Gold™ Strep A Test Kit is substantially equivalent to the TestPack® +Plus Strep A, (TestPack), Abbott Laboratories Inc., Chicago, IL. The Uni-Gold™ Strep A Test Kit is identical, or similar to, its predicate in terms of: intended use, antigen detected, technology/methodology, testing matrix, result interpretation, and clinical performance.
Trinity Biotech, plc Uni-Gold™ Strep A Test Kit pic. Registered in Ireland. Registration Number 183476 "soimh, CEO, 8 K Farrell | A O' Connell, Dr. | Walsh Dr. D Berger, Dr. A D Pronovos
510(k) Summary Page 9-2
1
Description of Device (21 CFR 807.92 (a)(4))
Immunoassay: Strep A antigen, when present, binds to the anti-Strep A antibody conjugated to a gold dye. As this complex travels along the membrane, it becomes immobilized at the test region, resulting in the formation of a red line. Excess antibodygold conjugate further migrates along the membrane and binds to the control region, forming another red line. In the absence of Strep A antigen, a red line will only be formed at the control region.
Intended Use (21 CFR 807.92 (a)(5))
The Trinity Biotech Uni-Gold™ Strep A Test Kit is a rapid immunoassay for the qualitative detection of Streptococcal A antigen from throat swabs, or the confirmation of beta-hemolytic colonies obtained from blood agar plates.
The Trinity Biotech Uni-Gold™ Strep A Test Kit is intended for use in hospital laboratories and physicians' offices as an aid in the diagnosis of Group A Streptococcal pharyngitis.
Similarities to the Predicate(s) (21 CFR 807.92 (a)(6))
A summary table of the similarities and differences between the Uni-Gold™ Strep A Test Kit and the predicate device (TestPack + Plus Strep A) follows.
2
| CHARACTERISTIC | UNI-GOLD TM Strep A | TESTPACK® +PLUS Strep A |
|---|---|---|
| Intended Use | qualitative detection of | |
| Group A Streptococcal | ||
| antigen from throat swabs, or | ||
| Group A confirmation from | ||
| culture plates | qualitative detection of Group A | |
| Streptococcal antigen from | ||
| throat swab specimens or | ||
| confirmation of presumptive | ||
| Group A Streptococcal colonies | ||
| recovered from culture | ||
| Antigen Detected | Group A Strep | Group A Strep |
| Methodology/Technology | Immunoassay: Strep A | |
| antigen, when present, binds | ||
| to the anti-Strep A antibody | ||
| conjugated to a gold dye. As | ||
| this complex travels along the | ||
| membrane, it becomes | ||
| immobilized at the test | ||
| region, resulting in the | ||
| formation of a red line. | ||
| Excess antibody-gold | ||
| conjugate further migrates | ||
| along the membrane and | ||
| binds to the control region, | ||
| forming another red line. In | ||
| the absence of Strep A | ||
| antigen, a red line will only | ||
| be formed at the control | ||
| region. | Immunoassay: A positive sample | |
| proceeds through the membrane, | ||
| and immobilizes the anti-Strep A | ||
| antibody coated colloid. The | ||
| sample and antibody-colloid | ||
| complex migrate through the | ||
| membrane to the Group A | ||
| capture region, and then onto the | ||
| end of the membrane. When the | ||
| end of the assay window turns | ||
| red, the result can be interpreted. | ||
| If a red plus sign appears in the | ||
| window, it indicates the presence | ||
| of Group A antigen. The absence | ||
| of the antigen will result in a | ||
| minus sign. | ||
| Testing Matrix | throat swab or culture | |
| confirmation | throat swab or culture | |
| confirmation | ||
| Result Interpretation | positive or negative for | |
| Strep A antigen | positive or negative for | |
| Strep A antigen | ||
| Assay Read Time | 5 minutes | 5 minutes |
| Conjugate Label | Colloidal Gold | Colloidal Gold |
| Extraction Time | 3 minutes | 3 minutes |
| Extraction Buffers | 2 | 2 |
| Testing Environment | professional use | professional use |
Similarities Between Uni-Gold™ Strep A Test Kit and TestPack +Plus Strep A
Differences Between Uni-Gold™ Strep A Test Kit and TestPack +Plus Strep A
| CHARACTERISTIC | UNI-GOLD™ Strep A | TESTPACK® +PLUS Strep A |
|---|---|---|
| Stability of Results | should be read after 5 minutes, | |
| not more than 10 minutes | should be read after 5 minutes | |
| Neutralizing buffer | none | one |
| Storage Temperature | 2-27° C (entire kit) | 2-8° C devices, |
| 2-27° C buffers |
3
Brief Discussion of Nonclinical Data (21 CFR 807.92(b)(1))
Laboratory studies were conducted to evaluate analytical sensitivity (lowest limit of detection) and analytical specificity (cross-reactivity testing from potential interferents). Summary description and results from those studies are provided below.
Analytical Sensitivity
Serial dilutions were prepared from colonies of Strep A cultures, and were tested with the Uni-Gold™ Strep A test Kit until the interpretations became "negative." The assay demonstrated a sensitivity of 1.0 x 105 cells/swab.
Analytical Specificity
The Uni-Gold™ Strep A Test Kit was used to test the following organisms at concentrations of approximately 1 x 10°. Negative results were obtained in all cases. NOTE: Staphylococcus aureus was tested at 1 x 106 organisms.
| Bordetella pertussis | Staphylococcus aureus |
|---|---|
| Branhamella catarrhalis | Staphylococcus epidermidis |
| Candida albicans | Streptococcus mutans |
| Corynebacterium diphtheria | Streptococcus pneumoniae |
| Escherichia coli | Streptococcus pyogenes, Lancefield group B |
| Hemophilus influenzae | Streptococcus pyogenes, Lancefield group C |
| Klebsiella pneumoniae | Streptococcus pyogenes, Lancefield group D |
| Neisseria gonorrhoeae | Streptococcus pyogenes, Lancefield group F |
| Neisseria meningitidis | Streptococcus pyogenes, Lancefield group G |
| Neisseria sicca | Streptococcus sanguis |
| Pseudomonas aeruginosa | Streptococcus sanguis |
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle or bird-like figure.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
FEB 1 1 1999
Trinity Biotech, PLC c/o Erika B. Ammirati Ammirati Regulatory Consulting 575 Shirlynn Court Los Altos, CA 94022
K982373 Re:
Trade Name: Uni-Gold™ Strep A Test Kit Regulatory Class: I Product Code: GTY Dated: January 4, 1999 Received: January 12, 1999
Dear Ms. Ammirati:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Page of
1982373 510(k) Number (if known). Strep A Test Kit Device Name: Gold
Indications For Use:
The Trinity Brotech Uni-Gold Steep A test Kit is a rapid for the gualitative detection of Streptococcal immunoassay from threat swaps or the confirmation of beta-hemolytic colonies obtained from blood agar It is intended for use in hospital laboratories and brians offices as an and in the dragmosis of Streptoco coal pharyng Nis
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Woody Dubois
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K982373
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)